Korro Bio, Inc.
Korro Bio develops RNA-editing oligonucleotides using its OPERA platform to modify native mRNA transcripts for rare and prevalent diseases.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 5Latest story
Korro Bio develops RNA-editing oligonucleotides using its OPERA platform to modify native mRNA transcripts for rare and prevalent diseases.
November 2026
October 2026
August 2026